mesmulogene ancovacivec

AXP000181.1 · Cancer vaccine

Platform
MVA
Targets
MUC1
Originator
Transgene
Sponsor
Transgene

Names

NameTypeSource
mesmulogene ancovacivecpreferred namecurator
TG4010codencit
MVA-MUC1-IL2synonymncit

Virus

Role
Vaccine vector
Family
Poxviridae
Virus
vaccinia virus (NCBI Taxonomy 10245)
Strain
MVA
Replication
non replicating
Modifications
MUC1 and IL-2 cassettes inserted into MVA
Transgenes
MUC1, IL2
Route
subcutaneous
Source
evidence

Cross-references

NCI Thesaurus
C2241
FDA UNII
WQQ9XZH2CC

Approvals

No regulatory approval recorded.

Clinical trials (5)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT03353675A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)CompletedPhase 22018-01-052019-11-2044Non Small Cell Lung Cancer Metastatic
NCT02823990TG4010 and Nivolumab in Patients With Lung CancerCompletedPhase 22016-12-142021-02-2413Recurrent Non-Small Cell Lung Carcinoma; Stage I Non-Small Cell Lung Cancer; Stage II Non-Small Cell Lung Cancer; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer
NCT01383148Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung CancerTerminatedPhase 2/32012-042015-07222Non-Small-Cell Lung Carcinoma
NCT00415818Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung CancerCompletedPhase 2/32005-122010-03148Carcinoma, Non-Small-Cell Lung
NCT00040170Vaccine Study of MVA-MUC1-IL2 in Patients With Prostate CancerTerminatedPhase 22002-0550Prostatic Neoplasms
Unconfirmed matches (1)

Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditionsMatched by
NCT00004881Vaccine Therapy in Treating Patients With Advanced CancerCompletedPhase 12000-04Unspecified Adult Solid Tumor, Protocol Specificname in intervention: MVA-MUC1-IL2

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 42684015A phase II multi-institutional single arm trial evaluating TG4010 vaccine plus nivolumab in non-small cell lung cancer.Oncoimmunology2026name in title: TG4010
PMID 28923084Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC.Journal for immunotherapy of cancer2017cited by trial NCT01383148
PMID 26727163TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.The Lancet. Oncology2016cited by trial NCT01383148
PMID 26207902Impact of TG4010 Vaccine on Health-Related Quality of Life in Advanced Non-Small-Cell Lung Cancer: Results of a Phase IIB Clinical Trial.PloS one2015name in title: TG4010
PMID 21069322A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings.Cancer immunology, immunotherapy : CII2011name in title: TG4010
PMID 22019520Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial.The Lancet. Oncology2011cited by trial NCT00415818
PMID 18931824MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure.Investigational new drugs2009name in title: MVA-MUC1-IL2
PMID 18594319A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2008name in title: MVA-MUC1-IL2
PMID 17935281Cancer immunotherapy: phase II clinical studies with TG4010 (MVA-MUC1-IL2).Journal of B.U.ON. : official journal of the Balkan Union of Oncology2007name in title: MVA-MUC1-IL2
PMID 12898638Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer.The journal of gene medicine2003name in abstract: TG4010

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 41002418Advances in Non-Small Cell Lung Cancer Cellular Immunotherapy: A Progress in Dendritic Cell, T-Cell, and NK Cell Vaccines.Cells2025name in abstract: TG4010
PMID 38470132Therapeutic vaccines for advanced non-small cell lung cancer.The Cochrane database of systematic reviews2024name in abstract: TG4010
PMID 29714142Efficacy and Safety of Antigen-specific Immunotherapy in the Treatment of Patients with Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis.Current cancer drug targets2019name in abstract: TG4010
PMID 30626434Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics.Journal for immunotherapy of cancer2019name in abstract: MVA-MUC1-IL2
PMID 28925793Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.Human vaccines & immunotherapeutics2018name in title: TG4010
PMID 28012777Sequential administration of a MVA-based MUC1 cancer vaccine and the TLR9 ligand Litenimod (Li28) improves local immune defense against tumors.Vaccine2017name in abstract: TG4010
PMID 28116088Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen.Journal for immunotherapy of cancer2017name in title: MVA-MUC1-IL2
PMID 27140406TG4010: a vaccine with a therapeutic role in cancer.Immunotherapy2016name in title: TG4010
PMID 27275498TG4010 immunotherapy: a novel weapon against advanced non-small cell lung cancer?Annals of translational medicine2016name in title: TG4010
PMID 27563655Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting.Annals of translational medicine2016name in abstract: TG4010
PMID 24143916Immunotherapy for lung cancer: ongoing clinical trials.Future oncology (London, England)2014name in abstract: TG4010
PMID 24196313Recent advances in immunotherapy for non-small-cell lung cancer.Human vaccines & immunotherapeutics2014name in abstract: TG4010
PMID 25030654Immunotherapeutic agents in non-small-cell lung cancer finally coming to the front lines.Current oncology reports2014name in abstract: TG4010
PMID 25496336Immunotherapy and lung cancer: current developments and novel targeted therapies.Immunotherapy2014name in abstract: TG4010
PMID 23401435Harnessing the immune system for the treatment of non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2013name in abstract: TG4010
PMID 23867519A new age for vaccine therapy in renal cell carcinoma.Cancer journal (Sudbury, Mass.)2013name in abstract: TG4010
PMID 27471692Therapeutic vaccines in non-small cell lung cancer.ImmunoTargets and therapy2013name in abstract: TG4010
PMID 22156658Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development.Annals of oncology : official journal of the European Society for Medical Oncology2012name in abstract: TG4010
PMID 22934285TG4010: A therapeutic vaccine against MUC1 expressing tumors.Oncoimmunology2012name in title: TG4010
PMID 21154139Biological Therapeutics Research and Development--GTCbio's Fifth Annual Conference. October 20-22, 2010, San Francisco, CA, USA.IDrugs : the investigational drugs journal2010name in abstract: TG4010
PMID 19649342Gateways to clinical trials.Methods and findings in experimental and clinical pharmacology2009name in abstract: TG4010
PMID 14988742Gateways to clinical trials.Methods and findings in experimental and clinical pharmacology2004name in abstract: MVA-MUC1-IL2
PMID 15648954TG-4010 Transgene.Current opinion in investigational drugs (London, England : 2000)2004name in title: TG4010

Notes

TG4010: MVA encoding MUC1 and human IL-2, subcutaneous, in first-line advanced NSCLC with chemotherapy; randomised phase 2b (TIME) reported 2016. MVA strain lineage recorded as MVA; specific MVA stock not verified here.

How to cite

mesmulogene ancovacivec (AXP000181.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000181.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.